MedTrace Logo

OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

NCT02145676 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2017-04-12

Study results available
· View outcomes & findings →

Summary

This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.

Conditions

Interventions

BIOLOGICAL

onabotulinumtoxinA

OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.

DRUG

placebo (normal saline)

Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02145676 on ClinicalTrials.gov